Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low‐dose etoposide on intergroup rhabdomyosarcoma study III: An interim report

Ruth Heyn, Fareed Khan, Lisa G. Ensign, Sarah S. Donaldson, Frederick Ruymann, Malcolm A. Smith, Teresa Vietti, Harold M. Maurer

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

The early occurrence of five cases of acute myeloid leukemia (AML) in children treated for primary rhabdomyosarcoma on the Intergroup Rhabdomyosarcoma Study III (IRS III) has prompted this report. These patients received cyclophosphamide and four received etoposide in addition to other agents. There were 1,062 eligible patients entered on IRS III between 1984 and 1991. Following surgery, treatment consisted of multiagent chemotherapy and radiotherapy in select clinical groups. Median follow‐up time is 3.7 years (range 0–7.4 years). Incidence densities and odds ratios for AML were calculated for various treatment groups. Five cases of secondary AML have been reported through August 1992. A single case of osteogenic sarcoma was reported in the same period and a patient with myelodys plastic syndrome has occurred since that time. Median time to development of AML was 39 months. Incidence density of AML for patients receiving neither cyclophosphamide nor etoposide was 0, for those receiving cyclophosphamide but no etoposide it was 7.6, and when both agents were given, it was 51.6. The odds ratios of AML for the latter two groups indicated a risk of AML which was seven times higher in the patients who received both agents. A history of breast cancer was present in all five families of patients with AML and several other cancers had occurred in three families. Preliminary analysis suggests a possible causal role for low‐dose etoposide in addition to that assumed for cyclophosphamide in the early development of AML among pediatric patients treated for rhabdomyosarcoma. © 1994 Wiley‐Liss, Inc.

Original languageEnglish (US)
Pages (from-to)99-106
Number of pages8
JournalMedical and Pediatric Oncology
Volume23
Issue number2
DOIs
StatePublished - 1994

Fingerprint

Rhabdomyosarcoma
Etoposide
Acute Myeloid Leukemia
Cyclophosphamide
Odds Ratio
Incidence
Osteosarcoma
Plastics
Radiotherapy
Pediatrics
Breast Neoplasms
Drug Therapy

Keywords

  • multiagent chemotherapy
  • radiotherapy
  • sarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low‐dose etoposide on intergroup rhabdomyosarcoma study III : An interim report. / Heyn, Ruth; Khan, Fareed; Ensign, Lisa G.; Donaldson, Sarah S.; Ruymann, Frederick; Smith, Malcolm A.; Vietti, Teresa; Maurer, Harold M.

In: Medical and Pediatric Oncology, Vol. 23, No. 2, 1994, p. 99-106.

Research output: Contribution to journalArticle

Heyn, Ruth ; Khan, Fareed ; Ensign, Lisa G. ; Donaldson, Sarah S. ; Ruymann, Frederick ; Smith, Malcolm A. ; Vietti, Teresa ; Maurer, Harold M. / Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low‐dose etoposide on intergroup rhabdomyosarcoma study III : An interim report. In: Medical and Pediatric Oncology. 1994 ; Vol. 23, No. 2. pp. 99-106.
@article{daa258c3225643c59af2d70df494224c,
title = "Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low‐dose etoposide on intergroup rhabdomyosarcoma study III: An interim report",
abstract = "The early occurrence of five cases of acute myeloid leukemia (AML) in children treated for primary rhabdomyosarcoma on the Intergroup Rhabdomyosarcoma Study III (IRS III) has prompted this report. These patients received cyclophosphamide and four received etoposide in addition to other agents. There were 1,062 eligible patients entered on IRS III between 1984 and 1991. Following surgery, treatment consisted of multiagent chemotherapy and radiotherapy in select clinical groups. Median follow‐up time is 3.7 years (range 0–7.4 years). Incidence densities and odds ratios for AML were calculated for various treatment groups. Five cases of secondary AML have been reported through August 1992. A single case of osteogenic sarcoma was reported in the same period and a patient with myelodys plastic syndrome has occurred since that time. Median time to development of AML was 39 months. Incidence density of AML for patients receiving neither cyclophosphamide nor etoposide was 0, for those receiving cyclophosphamide but no etoposide it was 7.6, and when both agents were given, it was 51.6. The odds ratios of AML for the latter two groups indicated a risk of AML which was seven times higher in the patients who received both agents. A history of breast cancer was present in all five families of patients with AML and several other cancers had occurred in three families. Preliminary analysis suggests a possible causal role for low‐dose etoposide in addition to that assumed for cyclophosphamide in the early development of AML among pediatric patients treated for rhabdomyosarcoma. {\circledC} 1994 Wiley‐Liss, Inc.",
keywords = "multiagent chemotherapy, radiotherapy, sarcoma",
author = "Ruth Heyn and Fareed Khan and Ensign, {Lisa G.} and Donaldson, {Sarah S.} and Frederick Ruymann and Smith, {Malcolm A.} and Teresa Vietti and Maurer, {Harold M.}",
year = "1994",
doi = "10.1002/mpo.2950230206",
language = "English (US)",
volume = "23",
pages = "99--106",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low‐dose etoposide on intergroup rhabdomyosarcoma study III

T2 - An interim report

AU - Heyn, Ruth

AU - Khan, Fareed

AU - Ensign, Lisa G.

AU - Donaldson, Sarah S.

AU - Ruymann, Frederick

AU - Smith, Malcolm A.

AU - Vietti, Teresa

AU - Maurer, Harold M.

PY - 1994

Y1 - 1994

N2 - The early occurrence of five cases of acute myeloid leukemia (AML) in children treated for primary rhabdomyosarcoma on the Intergroup Rhabdomyosarcoma Study III (IRS III) has prompted this report. These patients received cyclophosphamide and four received etoposide in addition to other agents. There were 1,062 eligible patients entered on IRS III between 1984 and 1991. Following surgery, treatment consisted of multiagent chemotherapy and radiotherapy in select clinical groups. Median follow‐up time is 3.7 years (range 0–7.4 years). Incidence densities and odds ratios for AML were calculated for various treatment groups. Five cases of secondary AML have been reported through August 1992. A single case of osteogenic sarcoma was reported in the same period and a patient with myelodys plastic syndrome has occurred since that time. Median time to development of AML was 39 months. Incidence density of AML for patients receiving neither cyclophosphamide nor etoposide was 0, for those receiving cyclophosphamide but no etoposide it was 7.6, and when both agents were given, it was 51.6. The odds ratios of AML for the latter two groups indicated a risk of AML which was seven times higher in the patients who received both agents. A history of breast cancer was present in all five families of patients with AML and several other cancers had occurred in three families. Preliminary analysis suggests a possible causal role for low‐dose etoposide in addition to that assumed for cyclophosphamide in the early development of AML among pediatric patients treated for rhabdomyosarcoma. © 1994 Wiley‐Liss, Inc.

AB - The early occurrence of five cases of acute myeloid leukemia (AML) in children treated for primary rhabdomyosarcoma on the Intergroup Rhabdomyosarcoma Study III (IRS III) has prompted this report. These patients received cyclophosphamide and four received etoposide in addition to other agents. There were 1,062 eligible patients entered on IRS III between 1984 and 1991. Following surgery, treatment consisted of multiagent chemotherapy and radiotherapy in select clinical groups. Median follow‐up time is 3.7 years (range 0–7.4 years). Incidence densities and odds ratios for AML were calculated for various treatment groups. Five cases of secondary AML have been reported through August 1992. A single case of osteogenic sarcoma was reported in the same period and a patient with myelodys plastic syndrome has occurred since that time. Median time to development of AML was 39 months. Incidence density of AML for patients receiving neither cyclophosphamide nor etoposide was 0, for those receiving cyclophosphamide but no etoposide it was 7.6, and when both agents were given, it was 51.6. The odds ratios of AML for the latter two groups indicated a risk of AML which was seven times higher in the patients who received both agents. A history of breast cancer was present in all five families of patients with AML and several other cancers had occurred in three families. Preliminary analysis suggests a possible causal role for low‐dose etoposide in addition to that assumed for cyclophosphamide in the early development of AML among pediatric patients treated for rhabdomyosarcoma. © 1994 Wiley‐Liss, Inc.

KW - multiagent chemotherapy

KW - radiotherapy

KW - sarcoma

UR - http://www.scopus.com/inward/record.url?scp=0028334509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028334509&partnerID=8YFLogxK

U2 - 10.1002/mpo.2950230206

DO - 10.1002/mpo.2950230206

M3 - Article

C2 - 8202048

AN - SCOPUS:0028334509

VL - 23

SP - 99

EP - 106

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 2

ER -